iiinova — where your digital self keeps evolving

cottonelucia.bsky.social

@cottonelucia.bsky.social

cottonelucia.bsky.social @cottonelucia.bsky.social · 09/06/2025

🚨 We’re hiring a Postdoc! Join our osteosarcoma research project @mariasecrier.bsky.social @fionafreeman.bsky.social. Funded by @littleprincesses.bsky.social 🧬🧫 🔹Cellular & molecular biology 🔹Cool 3D models 📍 UCL Cancer Institute, London 🗓️ July 1 📎 bit.ly/4kBCPt3 🌐 More info: lnkd.in/eahvf7Tg

bit.ly

UCL – University College London

UCL is consistently ranked as one of the top ten universities in the world (QS World University Rankings 2010-2022) and is No.2 in the UK for research power (Research Excellence Framework 2021).

043

Reposted by @cottonelucia.bsky.social

Lucy Brooks @brooks-lab.bsky.social · 19/05/2025

📣We’re hiring a Postdoc! Join my new lab at the University of Oxford to investigate therapy resistance in brain cancer. ⏰Deadline: 16 June 2025 Apply 👇 my.corehr.com/pls/uoxrecru... Boosts appreciated! #PostdocJobs #CancerResearch #BrainCancer

my.corehr.com

064

cottonelucia.bsky.social @cottonelucia.bsky.social · 09/06/2025

🚨 We’re hiring a Postdoc! Join our osteosarcoma research project with @secrierlab + @freemanfiona, funded by @LPTrustUK 🧬🧫 🔹Cellular & molecular biology 🔹Cool 3D models 📍 UCL Cancer Institute, London 🗓️ July 1 📎 bit.ly/4kBCPt3 🌐 More info: lnkd.in/eahvf7Tg

bit.ly

UCL – University College London

UCL is consistently ranked as one of the top ten universities in the world (QS World University Rankings 2010-2022) and is No.2 in the UK for research power (Research Excellence Framework 2021).

000

cottonelucia.bsky.social @cottonelucia.bsky.social · 16/03/2025

New Preprint Alert! 🚨 Targeting Metabolic Stress in Chordoma - with @AdamCribbs Could glutamyl-prolyl-tRNA synthetase (EPRS) inhibition be a new therapeutic avenue for #chordoma? Read our preprint here: www.biorxiv.org/content/10.1...

biorxiv.org

ATF4-Mediated Metabolic Stress Response as a Therapeutic Vulnerability in Chordoma

Chordoma, a rare primary bone malignancy, currently lacks effective targeted therapies. Despite surgical resection and adjuvant radiotherapy, prognosis remains poor. Recent preclinical studies have hi...

161